ACET Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Adicet Bio Inc (ACET) does not present a compelling buy opportunity for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. While the stock has shown some positive price movement and analysts maintain a Buy rating, the lack of significant financial growth, absence of recent news catalysts, and neutral trading sentiment suggest that it may be prudent to wait for clearer signals or stronger fundamentals before investing.
The MACD is positively expanding with a histogram of 0.16, indicating a bullish trend. RSI at 75.347 is in the neutral zone, and moving averages are converging, suggesting no strong directional bias. The stock is trading near resistance levels (R2: 8.406), which may limit further short-term upside.
Analysts maintain a Buy rating on the stock, citing potential milestones in 2026 and accelerating enrollment in autoimmune indications. The stock has an 80% chance of gaining 7.49% over the next month based on historical patterns.
EPS dropped by -12.45% YoY, and gross margin remains at
Additionally, no recent news or congress trading data is available to act as a catalyst.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$30.5M, which improved slightly by 6.23% YoY. EPS declined by -12.45% YoY to -4.43, and gross margin remained at 0%. Overall, financial performance is weak.
Analysts maintain a Buy rating but have significantly lowered price targets recently. H.C. Wainwright reduced the target from $50 to $27, citing higher long-term operating expenses, while Guggenheim reduced the target from $128 to $100, highlighting potential milestones in 2026 but acknowledging challenges.
